摘要
目的探讨当归补血汤联合重组人粒细胞刺激因子防治乳腺癌化疗后骨髓抑制的效果。方法将60例乳腺癌化疗患者随机分为治疗组与对照组各30例。治疗组给予当归补血汤及重组人粒细胞刺激因子治疗,对照组仅给予重组人粒细胞刺激因子治疗。对比2组骨髓抑制情况和化疗后感染情况。结果 2组患者化疗前白细胞计数比较差异无统计学意义（P〉0.05）;而治疗组化疗第7、14、21天白细胞计数高于对照组（P〈0.05）。对照组化疗前后白细胞水平变化差异无统计学意义（P〉0.05）。治疗组化疗后白细胞、粒细胞、血红蛋白、血小板Ⅲ-Ⅳ度抑制情况明显轻于对照组（P〈0.05）。在整个治疗周期中,治疗组感染发生率为3.3%（1/30）低于对照组的26.7%（8/30）（P〈0.05）。结论当归补血汤联合皮下注射重组人粒细胞刺激因子可防治乳腺癌化疗后骨髓抑制,值得临床推广应用。
Objective To observe the effect of angelica blood tonic soup combined with recombinant human granulocyte colony-stimulating factor in bone marrow suppression after chemotherapy of breast cancer. Methods 60 cases of patients with breast cancer treated by chemotherapy randomly divided into treatment group and control group,each of 30 cases. The control group treated by recombinant human granulocyte stimulating factor. The treatment group,on the basis of control group,treated by angelica blood tonic soup. After treatment,compared the bone marrow suppression and the incidence of infection after chemotherapy. Results The white blood cell count before chemotherapy has no statistically significant（ P〈0. 05）. The white blood cell count of treatment group in 7th,14 th,21th after chemotherapy were higher than that of control group,the difference was statistically significant（ P〉0. 05）. The white blood cell count before and after chemotherapy was no statistically significant（ P〉0. 05）. The inhibition of white blood cells,neutropenia,hemoglobin and platelet of treament group after chemotherapy were Lighter than that of control group（ P〈0. 05）. The infection incidence of treatment（ 3. 3%,1 /30） was lower than that of control group（ 26. 7%,8 /30）（ P〈0. 05）. Conclusion Angelica blood tonic soup combined with recombinant human granulocyte colony-stimulating factor in bone marrow suppression after chemotherapy of breast cancer has an good effect,worthy of clinical application.
出处
《临床合理用药杂志》
2015年第28期8-10,共3页
Chinese Journal of Clinical Rational Drug Use
关键词
当归补血汤
重组人粒细胞刺激因子
乳腺癌
化学治疗
Angelica blood tonic soup
Recombinant human granulocyte colony-stimulating factor
Breast cancer
Chemotherapy
